

SPORTS Trial

Investigator-Sponsored¹, Core-lab Adjudicated, Randomized Controlled Trial Evaluating Drug-Eluting Stent or Drug-coated balloons versus primary bare nitinol stent application in long SFA lesions



OBJECTIVE


Compare angiographic and clinical outcomes of TASC C/D SFA lesions after treatment with BMS v. DCB v. DES

TRIAL DESIGN

Investigator-sponsored | Prospective | Core-lab adjudicated | Multi-center | Three-arm randomization (1:1:1) of BMS v. DCB v. DES

KEY INCLUSION CRITERIA


SFA/PPA lesion lengths at least 130mm (treatment length \geq 150mm) | Rutherford classes 2–4 | Diameter stenosis \geq 70%



Eluvia DES Proved Statistically Superior to BMS in Long, Complex Lesions


- Significantly less in-lesion diameter stenosis at 1 year for Eluvia vs BMS ($p < 0.0001$)
- DCB was non-inferior to BMS in terms of diameter stenosis at 1 year.

1-YEAR ANGIOGRAPHIC DIAMETER STENOSIS



Eluvia DES Confirmed Superior Primary Patency Results Over 24 Months²

1- AND 2-YEAR PRIMARY PATENCY



* DCB in SPORTS trial was B. Braun SeQuent® Please Drug-Coated Balloon

1. Tepe, G. SPORTS Trial: Drug Eluting Stent or Primary Bare Nitinol Stent Application versus Drug Coated Balloons in Long SFA Lesions. Presented at TCT 24 Oct 2023.

2. Tepe, G. SPORTS Trial: Drug Eluting Stent or Primary Bare Nitinol Stent Application versus Drug Coated Balloons in Long SFA Lesions. Presented at Charing Cross 23 Apr 2025.

Calculated by Kaplan-Meier curve time to loss of primary patency defined as ultrasound-derived peak systolic velocity ratio of < 2.4 or TLR


High Rate of Bail-Out Stenting in DCB Arm

In long, complex lesions,

58%

of lesions treated with a DCB required a bail-out BMS which provided no additional clinical benefit versus BMS alone.

Late Lumen Loss and Freedom from CD-TLR Differed Statistically Across Groups, Favoring Eluvia DES



BASELINE CHARACTERISTICS

Patient Characteristics	BMS n=76	DCB n=74	DES n=74	Lesion Characteristics	BMS n=76	DCB n=74	DES n=74	p-value
Age (Years)	67	70	68	Mean Lesion Length (mm)	227	221	235	0.57
Male Gender (%)	72	66	60	Occlusion (%)	74	70	85	0.08
Diabetes Mellitus (%)	26	30	23	Occlusion length (mm)	151	175	179	0.18
Renal Disease (%)	3	12	8	RVD (mm)	5.2	5.0	5.3	0.01
Current Smoker (%)	58	60	55	MLD in lesion (mm)	0.3	0.4	0.2	0.18
				Mod/Severe Calcification (%)**	67.1	71.7	58.1	0.36
				Diameter stenosis in lesion (%)	94.2	92.6	96.8	0.10

** PACSS Grade 3/4 may be considered moderate to severe calcification
ELUVIA Drug-Eluting Vascular Stent System
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.